Clinical trials: Essential Hypertension.
Uncontrolled Hypertension
A Phase I Trial of QLS1410 in Healthy Chinese Adults and Participants With Mild Essential Hypertension
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and food effect of single and multiple ascending doses of QLS1410 in healthy Chinese adults and participants with mild…
- Trial name
- NCT07152444
- Testing
- QLS1410 (CYP11B2 inhibitor)
- Where
- China
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Diabetes Mellitus, Essential Hypertension
The Effect of Metformin on the Correlation Between Hyperinsulinemia and Hypertension
The objective of this study is to investigate the effect of metformin on the correlation between hyperinsulinemia and hypertension.
- Trial name
- NCT01342614
- Testing
- Fosinopril, Metformin
- Volunteers
- 140 people
- Sponsor
- China-Japan Friendship Hospital
Essential Hypertension
A Study to Evaluate the Safety and Pharmacokinetics After Oral Concurrent Administration of Fimasartan and Hydrochlorothiazide in Healthy Male Volunteers
To evaluate drug-drug interaction between fimasartan and hydrochlorothiazide.
- Trial name
- NCT00923533
- Testing
- Fimasartan, Hydrochlorothiazide
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Essential Hypertension
A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Candesartan Cilexetil Monotherapy
Compare the safety and efficacy of amlodipine besylate and candesartan cilexetil combination therapy on patients of essential hypertension who are not properly controlled by candesartan cilexetil monotherapy.
- Trial name
- NCT02368652
- Testing
- Candesartan cilexetil 16mg, Amlodipine 10mg, Candesartan cilexetil 16mg
- Where
- 19 sites in South Korea
- Volunteers
- 181 people
- Sponsor
- HK inno.N Corporation
Hypertension, Essential Hypertension
Evaluate the Efficacy and Safety of SPC1001 and Monotherapy in Patients With Essential Hypertension
This study purpose is to determine the appropriate combination drug dose by comparing safety and efficacy with placebo, candesartan, and amlodipine monotherapy after 8 weeks of administration of SPC1001 to patients with essential…
- Trial name
- SP-CAP-002 (NCT06212648)
- Testing
- SPC1001 High, SPC1001 Mid1, SPC1001 Mid2
- Where
- South Korea
- Volunteers
- 253 people
- Sponsor
- Shin Poong Pharmaceutical Co. Ltd.
Systolic Essential Hypertension
Non-pharmacological Treatment for Essential Isolated Systolic Hypertension in Elderly
The previous studies used the slow loaded breathing device for breathing training (Jones et al., 2010). It has been shown that slow loaded breathing training can reduce resting blood pressure and heart rate in essential…
- Trial name
- NCT02200926
- Testing
- Loaded breathing training, Unloaded breathing training
- Where
- Thailand
- Volunteers
- 30 people
- Sponsor
- Khon Kaen University
Essential Hypertension
A Phase 2 Dose Selection Trial of Candesartan Cilexetil and Amlodipine Besylate to Treat Essential Hypertension
The purpose of this study is to explore the optimal dose of fixed-dose combination of candesartan cilexetil and amlodipine besylate by examining the safety and efficacy of the combination therapy compared to each of the…
- Trial name
- NCT02059616
- Testing
- Amlodipine 5mg, Amlodipine 10mg, Candesartan Cilexetil 8mg
- Where
- 20 sites in South Korea
- Volunteers
- 384 people
- Sponsor
- HK inno.N Corporation
Hypertension
CKD-828(80/2.5mg) Pharmacokinetic Study
The purpose of this study is to evaluate the pharmacokinetic characteristics of CKD-828(Fixed Dose Combination Tablet; Telmisartan and S-Amlodipine) in healthy volunteer.
- Trial name
- NCT01246193
- Testing
- CKD-828(FDC), Combination Therapy
- Where
- South Korea
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Essential Hypertension
Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential Hypertension
This study assessed the efficacy of LCZ696 in Japanese patients with essential hypertension
- Trial name
- NCT01599104
- Testing
- LCZ696, Olmesartan
- Where
- 61 sites in Japan
- Volunteers
- 1,161 people
- Sponsor
- Novartis Pharmaceuticals
COPD (With - Without Rehabilitation), Diffuse Interstitial Lung Diseases
Development of a New Tool for Dyspnea Measurement in Chronic Respiratory Diseases
The purpose of this study is the psychometric validation of a self-administered dyspnea questionnaire, usable in clinical practice in order to assess dyspnea and its impact on patients with chronic respiratory diseases.
- Conditions
- COPD (With - Without Rehabilitation), Diffuse Interstitial Lung Diseases, Pulmonary Arterial Hypertension Primary or Secondary (Post Embolic .....), Cystic Fibrosis of the Adult
- Trial name
- DYSLIM (NCT02229994)
- Testing
- Cross sectional psychometric evaluation of a self-administered dyspnea questionnaire.
- Where
- France
- Volunteers
- 199 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Essential Hypertension
An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin for the Management of Essential Hypertension
This integrated assessment consists of two studies, 603A and 603B, to be carried out sequentially in a common study population. Participating subjects informed of the trial design and their consent to participate in both studies…
- Trial name
- NCT03514641
- Testing
- Bexagliflozin
- Where
- 87 sites in United States
- Volunteers
- 673 people
- Sponsor
- Theracos
Hypertension, Essential
Study of Nifedipine GITS and Candesartan Combination Compared to Monotherapy in Patients With Essential Hypertension
The purpose of this study is to determine the blood pressure lowering responses of various dose combinations of nifedipine GITS and candesartan as compared to treatment with each component on their own (monotherapy) and placebo…
- Trial name
- DISTINCT (NCT01303783)
- Testing
- Candesartan cilexetil (Atacand), 4 mg, Candesartan cilexetil (Atacand), 8 mg, Nifedipine GITS (Adalat, BAYA1040), 20 mg
- Where
- 157 sites in United States, Argentina and 11 more
- Volunteers
- 1,381 people
- Sponsor
- Bayer
Hypertension
Effect of Gut Microbiome Restoration on Primary Hypertension Via FMT
Mounting preclinical and clinical evidences have proved the causal role of gut microbiota on the pathogenesis of primary hypertension.
- Trial name
- FMT (NCT04406129)
- Testing
- FMT capsules
- Where
- 7 sites in China
- Volunteers
- 120 people
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Hypertension,Essential
Engaging Home-monitored Assessment to Navigate Clinical Decision-making
This study is testing a new app called ENHANCe, which is designed to help family doctors manage patients with high blood pressure using readings taken at home.
- Trial name
- ENHANCe (NCT07399912)
- Testing
- ENHANCe app, Teaching and training, Usual care
- Where
- Singapore
- Volunteers
- 116 people
- Sponsor
- SingHealth Polyclinics
Essential Hypertension
Prognostic Risk of Patients With Essential Hypertension for Cardiovascular Events (PROSPECT)
The registry study aims to determine serial biomarkers to prognosis of Essential Hypertension
- Trial name
- NCT03708601
- Where
- China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Beijing Institute of Heart, Lung and Blood Vessel Diseases
Hypertension
BRAVE Study With Uncontrolled Essential Hypertension (BRAVE Study)
This is an open-label, placebo run-in study to investigate the genetic and biomedical predictors of blood pressure response to bisoprolol.
- Trial name
- BRAVE (NCT02398929)
- Testing
- Bisoprolol 2.5 mg
- Where
- Hong Kong
- Volunteers
- 100 people
- Sponsor
- Chinese University of Hong Kong
Primary Hypertension
The Effect of Self-Titration and Predictors for Blood Pressure Control in Patients With Hypertension
This study aims to investigate the relationship among self-efficacy, anxiety, depressive symptoms, quality of life, lifestyle, heart rate variability and blood pressure control; and to examine the effects of self-titration…
- Trial name
- NCT03470974
- Testing
- Self-titration strategy
- Where
- Taiwan
- Volunteers
- 222 people
- Sponsor
- Tri-Service General Hospital (TSGH)
Essential Hypertension
A Study to Evaluate the Effectiveness and Safety of a Fixed Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With High Blood Pressure Who do Not Achieve Target Blood Pressure Following Treatment With Azilsartan Medoxomil Alone
The purpose of this study is to evaluate the efficacy and safety of the fixed dose combinations of azilsartan medoxomil plus chlorthalidone (40/12.5 and 40/25 mg), once daily, in participants with grades 2 or 3 essential…
- Trial name
- NCT01456169
- Testing
- Azilsartan medoxomil - chlorthalidone
- Where
- 108 sites in Bulgaria, Estonia and 12 more
- Volunteers
- 507 people
- Sponsor
- Takeda
Isolated Systolic Hypertension
Isolated Systolic Hypertension in the Elderly and Very Elderly
To evaluate the efficacy of long-term treatment of individually optimized doses of olmesartan medoxomil compared to nitrendipine in elderly and very elderly patients with isolated systolic hypertension.
- Trial name
- NCT00751829
- Testing
- olmesartan medoxomil + hydrochlorothiazide, if necessary, nitrendipine + hydrochlorothiazide, if necessary
- Where
- Germany
- Volunteers
- 417 people
- Sponsor
- Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Essential Hypertension
Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing of Aliskiren (150 mg (Bid) Twice a Day) in Treating Moderate Hypertension.
This study will compare the safety and efficacy of once daily dosing of aliskiren to twice daily dosing of aliskiren in patients with moderate hypertension
- Trial name
- NCT00654875
- Testing
- Aliskiren
- Where
- 3 sites in United States, Germany and 1 more
- Volunteers
- 328 people
- Sponsor
- Novartis